Cong Lin, Liao Yong, Yang Suteng, Yang Rongya
Graduate School, Third Military Medical University, chongqing, China.
Department of Dermatology, PLA Army General Hospital, Beijing, China.
PLoS One. 2016 Dec 8;11(12):e0167903. doi: 10.1371/journal.pone.0167903. eCollection 2016.
Trichosporon asahii (T. asahii) is the major pathogen of invasive trichosporonosis which occurred mostly in immunocompromised patients. The biofilms formation ability of T. asahii may account for resistance to antifungal drugs and results a high mortality rate. Sertraline, a commonly prescribed antidepressant, has been demonstrated to show in vitro and in vivo antifungal activities against many kinds of pathogenic fungi, especially Cryptococcus species. In the present study, the in vitro activities of sertraline alone or combined with fluconazole, voriconazole, itraconazole, caspofungin and amphotericin B against planktonic forms and biofilms of 21 clinical T. asahii isolates were evaluated using broth microdilution checkerboard method and XTT reduction assay, respectively. The fractional inhibitory concentration index (FICI) was used to interpret drug interactions. Sertraline alone exhibited antifungal activities against both T. asahii planktonic cells (MICs, 4-8 μg/ml) and T. asahii biofilms (SMICs, 16-32 μg/ml). Furthermore, SRT exhibited synergistic effects against T. asahii planktonic cells in combination with amphotericin B, caspofungin or fluconazole (FICI≤0.5) and exhibited synergistic effects against T. asahii biofilms in combination with amphotericin B (FICI≤0.5). SRT exhibited mostly indifferent interactions against T. asahii biofilms in combination with three azoles in this study. Sertraline-amphotericin B combination showed the highest percentage of synergistic effects against both T. asahii planktonic cells (90.5%) and T. asahii biofilms (81.0%). No antagonistic interaction was observed. Our study suggests the therapeutic potential of sertraline against invasive T. asahii infection, especially catheter-related T. asahii infection. Further in vivo studies are needed to validate our findings.
阿萨希毛孢子菌(T. asahii)是侵袭性毛孢子菌病的主要病原体,该病主要发生在免疫功能低下的患者中。阿萨希毛孢子菌的生物膜形成能力可能是其对抗真菌药物产生耐药性的原因,并导致高死亡率。舍曲林是一种常用的抗抑郁药,已被证明在体外和体内对多种致病真菌,尤其是隐球菌属具有抗真菌活性。在本研究中,分别使用肉汤微量稀释棋盘法和XTT还原试验评估了舍曲林单独或与氟康唑、伏立康唑、伊曲康唑、卡泊芬净和两性霉素B联合对21株临床分离的阿萨希毛孢子菌浮游菌和生物膜的体外活性。采用部分抑菌浓度指数(FICI)来解释药物相互作用。舍曲林单独对阿萨希毛孢子菌浮游细胞(MICs,4-8μg/ml)和阿萨希毛孢子菌生物膜(SMICs,16-32μg/ml)均表现出抗真菌活性。此外,舍曲林(SRT)与两性霉素B、卡泊芬净或氟康唑联合对阿萨希毛孢子菌浮游细胞表现出协同作用(FICI≤0.5),与两性霉素B联合对阿萨希毛孢子菌生物膜表现出协同作用(FICI≤0.5)。在本研究中,舍曲林与三种唑类联合对阿萨希毛孢子菌生物膜大多表现为无关相互作用。舍曲林-两性霉素B联合对阿萨希毛孢子菌浮游细胞(90.5%)和阿萨希毛孢子菌生物膜(81.0%)的协同作用百分比最高。未观察到拮抗相互作用。我们的研究表明舍曲林对侵袭性阿萨希毛孢子菌感染,尤其是导管相关的阿萨希毛孢子菌感染具有治疗潜力。需要进一步的体内研究来验证我们的发现。